GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
A number of experts from @CGTCatapult will be sharing their knowledge and experience in manufacturing cell and gene therapies at this year’s Cell and Gene Therapy Manufacturing Workshop, 11-12 March, London #manufacturing #GMPmanufacturing #CGTmfg19 - https://t.co/5VgUJ1jaUG
GAiT will be finalising the Agenda for its scientific meeting in L.A. 30 JUNE 2019 next week. Watch this space.
One week left for #ISCT2019 early registration rates! Prices go up Feb 23. Countdown is on until we meet in Melbourne! Register Now: https://t.co/JzUkyhtEY1
GAiT will speak on defining and assessing Quality for clinical-grade iPSCs at the International Society for Cell and Gene Therapy's Conference (ISCT2019) in Melbourne Friday, 31 MAY 2019 15:45-17:00 AEST.
MHRA announces contingency legislation covering regulation of medicines and medical devices in a no-deal Brexit scenario #regulation #regulatorynews #Brexit -
Contingency legislation covering regulation of medicines and medical devices in a no deal scenario
Legislation has been published which, in the event of the UK leaving the EU with no agreement, will cover the regulation of medicines, medical devices...
.@CGTCatapult's clinical trials database shows that there are 85 cell and gene therapy clinical trials ongoing in the UK #celltherapy #genetherapy #clinical trials - https://t.co/XkFKkiJL7K
We have now placed the audio and slides from the Donor Consent workshop up for members on the GAiT website (https://t.co/b4jQnk0Uxb ). Thanks again to @CCRM_ca 's Siofradh McMahon for very valuable input and indeed to all those who participated. #GAiT2019 #CCRM